<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640887</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS12150a</org_study_id>
    <nct_id>NCT00640887</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa</brief_title>
  <official_title>Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of the project is to evaluate rifabutin (RBT) as a replacement for rifampicin&#xD;
      (RMP), for the combined treatment of tuberculosis and HIV infection. RBT represents an&#xD;
      alternative to RMP for HIV infected patients as its half-life is longer and the enzymatic&#xD;
      induction effect appears to be less important on the associated antiretroviral therapy (ART)&#xD;
      drugs.&#xD;
&#xD;
      This phase II trial is to determine precisely the pharmacokinetics parameters of RBT in&#xD;
      combination with different ART regimens in Vietnamese HIV infected patients with pulmonary&#xD;
      tuberculosis, in order to define optimal doses that will be further tested in a larger phase&#xD;
      III trial comparing safety, tolerability and efficacy of RBT and RMP regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be offered to participated in the study after the first 6 weeks of the&#xD;
      nationally recommended TB treatment. All the enrolled patients will be switched to rifabutin&#xD;
      and randomized, two weeks later, to one of the three study ARV regimens. The RBT doses will&#xD;
      be then adapted to the allocated ARV regimen according to a cross over scheme. Three full&#xD;
      pharmacokinetics profile will be performed at different time point : before initiation of&#xD;
      ARV, after one month of the first RFB dosage and one month after the second RFB dosage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of rifabutine measured (a)before introduction of ART;(b)after ART initiation (two different doses of RBT in combination with efavirenz, nevirapine or lopinavir/ritonavir)</measure>
    <time_frame>2, 6 and 10 weeks after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of efavirenz, nevirapine and lopinavir/ritonavir in combination with two doses of rifabutine</measure>
    <time_frame>6 and 10 weeks after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : proportion of patients with grade 3 and grade 4 adverse events</measure>
    <time_frame>through out the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBT associated with EFV based ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBT associated with NVP based ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RBT associated with LPV/r based ART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifabutin in combination with efavirenz</intervention_name>
    <description>Ia. arm 1a:&#xD;
D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);&#xD;
Ib. arm 1b:&#xD;
D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifabutin in combination with nevirapine</intervention_name>
    <description>IIa. arm 2a:&#xD;
D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);&#xD;
IIb. arm 2b :&#xD;
D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifabutin in combination with lopinavir/ritonavir</intervention_name>
    <description>IIIa. arm 3a :&#xD;
D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);&#xD;
IIIb. arm 3b:&#xD;
D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks).</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pulmonary tuberculosis (proven by AFB positive sputum or culture)&#xD;
&#xD;
          -  Having completed and adhered to 6 wks of intensive phase TB chemotherapy&#xD;
&#xD;
          -  Positive HIV antibody and CD4 count &gt;50 /mm3 and &lt;=200&#xD;
&#xD;
          -  Weight &gt; 50 kg&#xD;
&#xD;
          -  No ART in the preceding 3 months&#xD;
&#xD;
          -  No more than 2 weeks or ART previously&#xD;
&#xD;
          -  No grade 3 or 4 clinical or laboratory findings&#xD;
&#xD;
          -  Negative pregnancy test and appropriate contraceptive measures during the duration of&#xD;
             the trial for female of childbearing age&#xD;
&#xD;
          -  Having a firm home address that is readily accessible&#xD;
&#xD;
          -  Karnofsky score&gt;=80%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of TB within the 3 years preceding the presenting episode of TB&#xD;
&#xD;
          -  Previous treatment for MDR TB&#xD;
&#xD;
          -  Concomitant OI requiring additional anti-infectious treatment&#xD;
&#xD;
          -  Formal contraindication to any drug used in the trial&#xD;
&#xD;
          -  Diabetes mellitus requiring drug treatment&#xD;
&#xD;
          -  Recreational drug or alcohol abuse&#xD;
&#xD;
          -  History of drug hypersensitivity to TB or related medications&#xD;
&#xD;
          -  Interrupted TB therapy for more than 1 week&#xD;
&#xD;
          -  Less than 90% adherent to first 6 weeks of intensive phase chemotherapy&#xD;
&#xD;
          -  Mental illness that could impair ability to give informed consent or result in poor&#xD;
             adherence to trial protocol and therapy&#xD;
&#xD;
          -  Neutropenia &lt;1200 /L, anaemia &lt;6.8 g/dL, liver function test &gt; grade 2&#xD;
&#xD;
          -  Requiring concomitant medications that may potentially interact with study drugs&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Karnofsky score &gt;80%&#xD;
&#xD;
          -  Any condition rendering the patient unable to understand the nature, scope, and&#xD;
             possible consequences of thes study and to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony D Harries, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The international Union Against Tuberculosis and Lung Diseases (IUATLD), Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander PYM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Council, South Africa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit for Clinical and Biomedical TB Research (Medical Research Council)</name>
      <address>
        <city>Durban</city>
        <zip>4067</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2008</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Claire Rekacewicz</name_title>
    <organization>French National Agency for Research on AIDS and Viral Hepatitis</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>Rifabutin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>South Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

